ANB032, an Investigational BTLA Agonist Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and Prolonged Survival in a Mouse Model of Graph versus Host Disease

Eric Hare, Matthew Hsu, Cheryl Schendel, Chris Haines, Pejman Soroosh, Stephen Parmley, Martin Dahl, Paul Lizzul AnantysBio, San Diego, CA, USA

ABSTRACT

DECENSE


BACKGROUND

- B and T Lymphocyte Attenuator (BTLA) belongs to a family of co-inhibitory checkpoint receptors critical for immune system regulation, and is expressed preferentially on activated T cells, B cells, and dendritic cells (DCs), which are key contributors to inflammatory diseases
- ANB032 is an investigational BTLA agonist antibody that has been shown to reduce activated T cell proliferation, reduce inflammatory cytokine secretion (Th1, Th2, Th17, Th22), and modulate DC function while inducing Tregs¹
- Atopic dermatitis (AD) is a systemic, heterogenous inflammatory disease with pathogenesis driven by Th1, Th2, Th17, Th22, and DCs, both in the skin and in the periphery therefore ANB032 may potentially play a role in reducing inflammation and restoring immune homeostasis
- ANB032 and two reference BTLA agonists were evaluated to determine the effect of potency and the blocking of the natural HVEM/BTLA binding interaction in a humanized mouse model of GvHD (**Table 1**)
- The effect of BTLA agonism on inflammatory cytokine secretion was investigated with AD patient-derived peripheral blood mononuclear cells (PBMCs) in vitro

ibody characteristics of ANB032, Ref1 & R			
	ANB032	Ref1	Ref2
HVEM Sparing	\checkmark	\checkmark	×
FcR Engagement	\checkmark	×	×

Table 1. Description of BTLA agonists

Proposed Mechanism of Action for ANB032



Δ

- ANB032: IgG4 antibody (non-depleting) Binds to BTLA on membrane proximal
- Fc receptor binding profile contributes to differentiated potency Non-blocking of HVEM engagement
- ANB032's agonist signal modulates
- Inhibits activated T cell proliferation
- Reduces inflammatory cytokine secretion
- Modulates DC function, including inducing

METHODS


Humanized Mouse Model GvHD

- NOD-skid IL-2rynull mice were engrafted with human PBMCs one day prior to 4-week BiW dosing with BTLA agonist antibodies or isotype control (Figure 1)
- Blood was collected for fluorescence-activated cell sorting (FACS) analysis at study day 18 midpoint (determined when isotype control animals exhibited GvHD manifestations) (**Figure 2**)
- Clinical observations of survival, body weight (BW), and disease activity index (DAI: fur skin, posture, and activity) were collected twice weekly (BiW) (Figure 3)
- Inflammatory cytokines levels were measured from plasma collected at midpoint (SD18) (Figure 4)


AD Patient-Derived PBMCs

PBMCs from AD donors were treated with anti-CD3 and anti-CD28 in vitro for 72h to stimulate T cell proliferation, in the presence of ANB032 or isotype control mAb. Supernatants were collected for analysis by MSD to measure inflammatory cytokine secretion (Figure 5)

Humanized Mouse Model of GvHD









ist Ref1 🔻 BTLA Agonist Ref2

ANB032 Resulted in Prolonged Survival and Reduced Disease Activity Index



Isotype Control • ANB032 ▼ BTLA Agonist Ref1 ▼ BTLA Agonist Ref2 Figure 3. Evaluation of clinical observations (survival, body weight, and disease activity index) and human T cell expansion

ANB032 Reduced Inflammatory Cytokines



Isotype Co ANB032 T BTLA Ag BTLA Agor

nmatory cytokines were evaluated at Study Day 18 in the GvHD mode Figure 4. Plasma infla ANB032 Reduced Th1, Th2, Th17 & Th22 Cytokine

Secretion in AD Patient-derived PBMCs in Vitro of Th1 Cytoki of Th17 Cytokir Reducti ecretion 80 % IL-17A 6 IFN₇ of Th2 Cyte of Th22 Cvt % IL-22 % IL-13

Antibody (nM retion in AD patie Figure 5. In vitro evaluation of IFN-y, IL-17A, IL-13, and IL-22 se

CONCLUSIONS

- In a humanized mouse model of GvHD, ANB032:
- Reduced T cell expansion and inflammatory cytokines
- Demonstrated superior in vivo efficacy on key endpoints, including prolonged survival, maintained BW and an overall reduced DAI, compared to reference BTLA agonist antibodies
- Demonstrated the importance of HVEM sparing (not blocking HVEM), the natural BTLA ligand, resulting in enhanced potency when compared to an HVEM blocking anti-BTLA reference
- ANB032 reduced Th1, Th2, Th17 and Th22 inflammatory cytokine secretion from atopic dermatitis patient-derived PBMCs
- ANB032 is being evaluated in an ongoing Phase 2 study in moderate-to-severe AD (NCT05935085)

REFERENCES

1. Muench, et al. Presented at AAD 2024. ACKNOWLEDGEMENTS

- 1. This research was supported by Anaptys
 - Author disclosures: All authors are employees of Anaptys This research was previously presented at American Association of Immunology, May 2024
- Presented at European Society of Dermatological Research 4-7 September 2024, Lisbon, Portugal

3



nt-derived PBMCs